FIGURE 4 Effect of ACCi, Feno, and Res treatment as monotherapies or in combination with ACCi in the choline‐deficient high‐fat diet (CDHFD) rat model. (A–D) Quantification and representative images of hepatic picrosirius red (PSR) staining, and alpha–smooth muscle actin (α‐SMA + ), and clusters of differentiation 68 (CD68 + ) area as assessed by immunohistochemistry. (E) Terminal hepatic expression of fibrosis, fibrogenesis, and immune markers; data are presented as fold change relative to chow. Data are presented as mean ± SEM ( n  = 10–15 animals/ group); * p  ≤ 0.05, ** p  ≤ 0.01, *** p  ≤ 0.001, **** p  ≤ 0.0001 versus vehicle;  † 
 p  ≤ 0.05,  †† 
 p  ≤ 0.01,  ††† 
 p  ≤ 0.001,  †††† 
 p  ≤ 0.0001 versus ACCi monotherapy, or as indicated;  ‡ 
 p  ≤ 0.05,  ‡‡ 
 p  ≤ 0.01,  ‡‡‡ 
 p  ≤ 0.001,  ‡‡‡‡ 
 p  ≤ 0.0001 versus Feno, Res low , or Res high  monotherapy. Abbreviation: TIMP1, tissue inhibitor of metalloproteinase 1.